About Us
Bloom Advance Capital is a USD investment firm backed by a consortium of corporate leaders. Our limited partners include exceptional entrepreneurs and global companies spanning technology, consumer, healthcare, and trade.
We invest with deep sector conviction and a long-term perspective. With particular expertise in technology and healthcare, our team combines capital with strategic insight to support founders and operators in scaling transformational businesses. Beyond funding, we work closely with our portfolio companies to unlock growth, drive innovation, and create lasting value.
Partners
Yale, Managing Partner
A seasoned financial executive with over 25 years of global investment experience, Yale previously served as Managing Director and Head of Greater China Private Equity & Structured Investment at Macquarie Group. His earlier roles include positions at Deutsche Bank, Credit Suisse, Commonwealth Bank of Australia, and Bank of Boston, with a career spanning Singapore, the United States, and Hong Kong.
He has led landmark transactions for leading Chinese private enterprises facilitating over $3 billion in cross-border capital raises.
Brian, Managing Partner
With extensive experience across innovation and finance, Brian has held roles at Morgan Stanley Securities and Morgan Stanley Asia’s Financial Sponsors Group, where he worked with sovereign wealth funds, corporate venture arms, family offices, and PE firms worldwide. He previously led the healthcare investment group at SPDB International, where he advised on the IPOs of several leading medical enterprises.
He also founded SuperG.AI, one of the first autonomous driving solution providers in China to achieve commercial deployment in full vehicle platforms. The company holds over 20 patents. Previously, he served as an early-stage investor and corporate innovation lead for Plug and Play Tech Center’s China operations.
He has participated in IPOs and strategic financings of AI and healthcare leaders, including InnoCare Pharma, Hepalink, WeRide, JW Therapeutics, Horizon Robotics, and OSL, with total transaction value exceeding $2 billion.